Endovascular Engineering Appoints Dan Rose as Chief Executive Officer

August 20, 2024—Endovascular Engineering, Inc. (E2), a medical device company developing clot removal technologies for venous thromboembolism, has named Dan Rose as Chief Executive Officer (CEO).

E2 highlights that Rose most recently served as CEO of LimFlow SA, a company focused on limb salvage for patients with chronic limb-threatening ischemia. He joined LimFlow as the first employee and successfully guided the company through its acquisition by Inari Medical, Inc., which was completed in November 2023. Previously, Rose served as Vice President and General Manager Europe for Direct Flow Medical; led commercial and clinical activities at Sequana Medical AG; and held successive commercial leadership roles at Medtronic in Europe. Rose has a BA and MA from the University of Virginia in Charlottesville, Virginia. He earned an MBA from Virginia’s Darden School of Business.

The company advised that its former CEO and founding team member Mike Rosenthal will continue as Chief Operating Officer and remain on the company’s Board of Directors. He will also continue in his role as Founder and General Partner at Inventure Group, LLC, where E2 was incubated.

In February 2024, E2 announced the enrollment and treatment of the first patient in the pivotal phase of its ENGULF United States clinical trial that will evaluate the safety and efficacy of the company’s Helo thrombectomy system for the treatment of pulmonary embolism (PE) to support an application for FDA approval of the device.

“Under Mike’s leadership, the team has achieved remarkable milestones, positioning E2 to successfully complete its ENGULF pivotal trial and advance towards 510(k) clearance from the FDA,” commented Rose in E2’s press release. “I am deeply honored to lead this talented team with the mission of establishing the Helo PE thrombectomy system as the preferred option for PE treatment.”